PuraPharm Corporation Limited (1498.HK)
HKD 0.49
(0.0%)
HKD 0.49
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 689.65 Million HKD | -8.92% |
| 2022 | 757.18 Million HKD | -5.72% |
| 2021 | 803.13 Million HKD | -6.51% |
| 2020 | 859.06 Million HKD | 0.11% |
| 2019 | 858.08 Million HKD | 11.31% |
| 2018 | 770.88 Million HKD | 3.49% |
| 2017 | 744.89 Million HKD | 83.59% |
| 2016 | 405.74 Million HKD | 78.25% |
| 2015 | 227.62 Million HKD | -19.99% |
| 2014 | 284.49 Million HKD | 3.45% |
| 2013 | 274.99 Million HKD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 651.26 Million HKD | -5.57% |
| 2023 Q2 | 729.29 Million HKD | -3.68% |
| 2023 FY | 689.65 Million HKD | -8.92% |
| 2023 Q4 | 689.65 Million HKD | -5.44% |
| 2022 FY | 757.18 Million HKD | -5.72% |
| 2022 Q4 | 757.18 Million HKD | 4.18% |
| 2022 Q2 | 726.78 Million HKD | -9.51% |
| 2021 FY | 803.13 Million HKD | -6.51% |
| 2021 Q4 | 803.13 Million HKD | -3.42% |
| 2021 Q2 | 831.54 Million HKD | -3.2% |
| 2020 Q4 | 859.06 Million HKD | 13.29% |
| 2020 Q2 | 758.28 Million HKD | -11.63% |
| 2020 FY | 859.06 Million HKD | 0.11% |
| 2019 FY | 858.08 Million HKD | 11.31% |
| 2019 Q4 | 858.08 Million HKD | 4.14% |
| 2019 Q2 | 824 Million HKD | 6.89% |
| 2018 Q4 | 770.88 Million HKD | 5.14% |
| 2018 FY | 770.88 Million HKD | 3.49% |
| 2018 Q2 | 733.21 Million HKD | -1.57% |
| 2017 FY | 744.89 Million HKD | 83.59% |
| 2017 Q4 | 744.89 Million HKD | 4.72% |
| 2017 Q2 | 711.35 Million HKD | 75.32% |
| 2016 Q4 | 405.74 Million HKD | 32.35% |
| 2016 FY | 405.74 Million HKD | 78.25% |
| 2016 Q2 | 306.57 Million HKD | 34.69% |
| 2015 FY | 227.62 Million HKD | -19.99% |
| 2015 Q4 | 227.62 Million HKD | -20.47% |
| 2015 Q2 | 286.22 Million HKD | 0.61% |
| 2014 FY | 284.49 Million HKD | 3.45% |
| 2014 Q4 | 284.49 Million HKD | 0.0% |
| 2013 FY | 274.99 Million HKD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 142.28 Million HKD | -384.707% |
| Grand Pharmaceutical Group Limited | 7.24 Billion HKD | 90.481% |
| Extrawell Pharmaceutical Holdings Limited | 170.4 Million HKD | -304.708% |
| Wai Yuen Tong Medicine Holdings Limited | 709.65 Million HKD | 2.819% |
| Qianhai Health Holdings Limited | 94 Million HKD | -633.648% |
| Lee's Pharmaceutical Holdings Limited | 930.06 Million HKD | 25.849% |
| Essex Bio-Technology Limited | 903.78 Million HKD | 23.693% |
| Tongfang Kontafarma Holdings Limited | 665.38 Million HKD | -3.646% |
| SSY Group Limited | 4.49 Billion HKD | 84.654% |
| JBM (Healthcare) Limited | 366.75 Million HKD | -88.042% |
| Jacobson Pharma Corporation Limited | 1.09 Billion HKD | 36.758% |
| China Resources Pharmaceutical Group Limited | 168.46 Billion HKD | 99.591% |